Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Assets (2023 - 2025)

Historic Assets for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $39.8 million.

  • BioLineRx's Assets fell 2453.07% to $39.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.8 million, marking a year-over-year decrease of 2453.07%. This contributed to the annual value of $38.9 million for FY2024, which is 3913.81% down from last year.
  • BioLineRx's Assets amounted to $39.8 million in Q3 2025, which was down 2453.07% from $43.3 million recorded in Q2 2025.
  • In the past 5 years, BioLineRx's Assets ranged from a high of $68.6 million in Q1 2023 and a low of $38.9 million during Q4 2024
  • For the 3-year period, BioLineRx's Assets averaged around $52.6 million, with its median value being $52.7 million (2024).
  • Within the past 5 years, the most significant YoY rise in BioLineRx's Assets was 960.36% (2024), while the steepest drop was 3913.81% (2024).
  • Over the past 3 years, BioLineRx's Assets (Quarter) stood at $63.9 million in 2023, then crashed by 39.14% to $38.9 million in 2024, then grew by 2.31% to $39.8 million in 2025.
  • Its Assets was $39.8 million in Q3 2025, compared to $43.3 million in Q2 2025 and $43.5 million in Q1 2025.